Press release from the Annual General Meeting May 10, 2017

The Annual General Meeting (AGM) of Vicore Pharma Holding AB (publ) was held today May 10, 2017. The AGM passed resolutions regarding, among other thing, the following:

Accounts 2016
It was resolved to adopt the profit and loss account and the balance sheet of the company and the consolidated income statement and consolidated balance sheet and profit and loss account. It was resolved the the directors of the board and the managing director during 2016 be discharged from liability during the financial year of 2016, The Annual General Meeting resolved that no dividend will be distributed for the financial year 2016.

Board of Directors
The AGM resolved to appoint five board members and no deputy board member. The appointed members of the Board is Göran Wessman, Peter Ström, Kjell Stenberg, Leif Darner and Göran Arvidsson.

Chairman of the Board
Leif Darner was elected new Chairman of the Board.

Remuneration to the Board of Directors
The AGM also resolved that  remuneration should be paid with SEK 250,000 to the Chairman of the Board and 75,000 SEK to other Board members who are not employed by the company.

Auditor
The AGM resolved to re-elect auditing firm EY with Stefan Kylebäck as principal auditor for the period until next AGM.

Resolution on the Issue of new shares
The Annual General Meeting resolved to authorize the Board of directors to resolve on, on one or several occasions, until the next AGM, issue of shares and/or convertibles and/or warrants against cash payment and/or with a clause or set-off or otherwise on terms and conditions may deviate from the shareholders' preferential rights.

The number of shares to be issued and the number of shares that may be subscribed for through warrants and the number of shares that may be subscribed for by converting a convertible  t  shall amount to a maximum of 4,000,000 shares.

For further information, please contact:

Leif Darner, Chairman of the Board
Tel: +46 705 79 04 62
or e-mail: leif.darner@vicorepharma.com

Per Jansson, CEO

Tel: + 46 70 17 47 46 or e-mail: per.jansson@vicorepharma.com

This is information which Vicore Pharma Holding AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact person's auspices, for publication May 10, 2017 at. 16:40 CET.

About Vicore Pharma Holding
Vicore Pharma, a Nasdaq Stockholm First North listed holding-, and management company. Vicore Pharma develops drugs targeting stimulation of the AT2 Receptor (AT2R) in the Renin-Angiotensin-System (RAS). The company vision is to establish AT2-agonists as a new effective class of small molecule drugs. Our lead candidate, C21 will be focused on the indication Idiopatic pulmonary fibrosis (IPF). For further information, please refer to www.vicorepharma.com

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe